Back to Browse Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 3

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Authors Baptist Gallwitz

Published Date May 2010 Volume 2010:3 Pages 117—124

DOI http://dx.doi.org/10.2147/DMSO.S4857

Published 10 May 2010

Baptist Gallwitz

Dept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, Germany

Abstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly selective for DPP-4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4 inhibitors elevate plasma concentrations of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This effect results in a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion without an intrinsic risk for hypoglycemia. In comparison to sulfonylureas and thiazolidinediones that promote weight gain, DPP-4 inhibitors are weight neutral. Saxagliptin has been approved by the FDA for the US and by the EMEA for Europe in 2009. Clinical trials showed a dose-dependent inhibition of DPP-4 by saxagliptin in doses ranging from 2.5 to 100 mg daily without serious side effects. Type 2 diabetic patients receiving 5 mg to 10 mg saxagliptin once daily had a significant lowering of HbA1c and glycemic parameters along with good tolerability and safety. Saxagliptin has demonstrated a good efficacy for glycemic parameters in various patient populations either in monotherapy or in combination with metformin and other oral antidiabetic drugs as well as a favorable cardiovascular profile. With its high selectivity for DPP-4 and its clinical and cardiovascular profile, saxagliptin is an attractive novel DPP-4 inhibitor.

Keywords: type 2 diabetes, diabetes therapy, DPP-4 inhibitors, incretin based therapy, GLP-1, saxagliptin

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Novel targeted therapies in chordoma: an update

Di Maio S, Yip S, Al Zhrani GA, Alotaibi FE, Al Turki A, Kong E, Rostomily R

Therapeutics and Clinical Risk Management 2015, 11:873-883

Published Date: 26 May 2015

Evaluation of combined famotidine with quercetin for the treatment of peptic ulcer: in vivo animal study

Abourehab MA, Khaled KA, Sarhan HA, Ahmed OA

Drug Design, Development and Therapy 2015, 9:2159-2169

Published Date: 13 April 2015

Amoxicillin concentrations in relation to beta-lactamase activity in sputum during exacerbations of chronic obstructive pulmonary disease

Brusse-Keizer M, VanderValk P, van der Zanden RW, Nijdam L, van der Palen J, Hendrix R, Movig K

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:455-461

Published Date: 3 March 2015

Self-assembled polymeric nanoparticles as new, smart contrast agents for cancer early detection using magnetic resonance imaging

Mouffouk F, Simão T, Dornelles DF, Lopes AD, Sau P, Martins J, Abu-Salah KM, Alrokayan SA, Rosa da Costa AM, dos Santos NR

International Journal of Nanomedicine 2015, 10:63-76

Published Date: 17 December 2014

Comparison of bone tissue trace-element concentrations and mineral density in osteoporotic femoral neck fractures and osteoarthritis

Karaaslan F, Mutlu M, Mermerkaya MU, Karaoğlu S, Saçmaci Ş, Kartal Ş

Clinical Interventions in Aging 2014, 9:1375-1382

Published Date: 18 August 2014

Small-aperture corneal inlay in patients with prior radial keratotomy surgeries

Huseynova T, Kanamori T, Waring GO IV, Tomita M

Clinical Ophthalmology 2013, 7:1937-1940

Published Date: 26 September 2013

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010